www.philly.com

www.philly.com
Share

www.philly.com

 •  September 21

Delaware County has become the first county in Pennsylvania to sue some of the largest manufacturers of addictive painkillers, joining a growing number of municipalities nationwide that have taken that step with the hope of stemming the deadly opioid epidemic. Delaware County District Attorney Jack Whelan announced the lawsuit Thursday afternoon...

www.philly.com

 •  August 30

Bensalem plans to sue pharmaceutical manufacturers in hopes of recouping tens of millions of dollars spent fighting and opioid epidemic that officials believe was fueled by greedy drug companies. Township officials said they looked forward to becoming the first jurisdiction in the Philadelphia region to join a small but growing list of states,...

www.philly.com

 •  August 24

Recent actions by federal and state officials have put opioid manufacturers in the spotlight at a time when drug overdoses are a national crisis. Efforts meant to fight prescription pain medication abuse may be helping company profit margins more than consumers and patients. In July, the Food and Drug Administration (FDA) asked Endo Pharmaceuticals...

www.philly.com

 •  April 4

A leading Democratic senator is investigating the nation’s top opioid manufacturers to determine whether they contributed to overuse of the painkillers at the center of a deadly addiction crisis that has led to nearly 200,000 overdose deaths in the past 15 years. Sen. Claire McCaskill of Missouri on Mar. 28 asked the manufacturers of the nation’s...

www.philly.com

 •  February 23

Incyte Corp., a biopharmaceutical firm in Wilmington, announced Thursday a research collaboration with the Abramson Cancer Center at the University of Pennsylvania to come up with new immuno-oncology drugs to treat cancers. Incyte, founded by former employees of DuPont Pharmaceuticals in 2002, will fund the research. Financial terms were not...

www.philly.com

 •  February 14

Teva Pharmaceutical Industries, Ltd., has been trying to buy fellow giant generic drugmaker Mylan, Inc., and the latest step to emerge was the purchase of chunks of stock on the open market. Teva said it had bought a 1.35% stake in Mylan at prices ranging between $69 and $71 per share. "Acquiring shares of Mylan underscores our commitment to...